A carregar...
Is Fidaxomicin Worth the Cost? An Economic Analysis
Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decisio...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3719891/ https://ncbi.nlm.nih.gov/pubmed/23704121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cit346 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|